Livia Gheorghe1, Benno J W M Rensing1, Jan A S Van der Heyden2, Frank D Eefting1, Martijn C Post3, Bushra Rana4, Martin J Swaans5. 1. Interventional Cardiology Unit, Cardiology Department, St. Antonius Hospital, Nieuwegein, The Netherlands. 2. Interventional Cardiology Unit, AZ Sint-Jan Hospital, Brugge, Belgium. 3. Cardiac Imaging Unit, Cardiology Department, St. Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, The Netherlands. 4. Department of Cardiology, Royal Papworth Hospital, Cambridge, UK. 5. Cardiac Imaging Unit, Cardiology Department, St. Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, The Netherlands. m.swaans@antoniusziekenhuis.nl.
Abstract
PURPOSE OF REVIEW: This review aims to provide an updated overview and a clinical perspective on novel transcatheter tricuspid valve interventions (TTVI), highlighting potential challenges and future directions. RECENT FINDINGS: Severe tricuspid regurgitation (TR) is a predictor of mortality. However, a sizeable number of patients remain untreated until the end-stage when cardiac surgery presents a prohibitive risk. The emergent need in finding a treatment for patients with TR, deemed for surgery options, has encouraged the development of TTVI. These procedures mimic classical surgery techniques and are mainly divided in four categories: annuloplasty and coaptation devices, edge-to-edge techniques and transcatheter tricuspid valve replacement. Early studies showed promising results, but long-term follow-up data are not available. For patients with severe TR and high surgical risk, several percutaneous options are available. However, these therapies are in a growing phase and bigger studies and long term follow-up are needed to prove their efficacy.
PURPOSE OF REVIEW: This review aims to provide an updated overview and a clinical perspective on novel transcatheter tricuspid valve interventions (TTVI), highlighting potential challenges and future directions. RECENT FINDINGS: Severe tricuspid regurgitation (TR) is a predictor of mortality. However, a sizeable number of patients remain untreated until the end-stage when cardiac surgery presents a prohibitive risk. The emergent need in finding a treatment for patients with TR, deemed for surgery options, has encouraged the development of TTVI. These procedures mimic classical surgery techniques and are mainly divided in four categories: annuloplasty and coaptation devices, edge-to-edge techniques and transcatheter tricuspid valve replacement. Early studies showed promising results, but long-term follow-up data are not available. For patients with severe TR and high surgical risk, several percutaneous options are available. However, these therapies are in a growing phase and bigger studies and long term follow-up are needed to prove their efficacy.
Authors: William D Meador; Mrudang Mathur; Gabriella P Sugerman; Tomasz Jazwiec; Marcin Malinowski; Matthew R Bersi; Tomasz A Timek; Manuel K Rausch Journal: Acta Biomater Date: 2019-11-22 Impact factor: 8.947